Menlo Therapeutics, Inc.
Menlo Therapeutics, Inc. is listed today as Yarrow Bioscience, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2023 | $88 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Jul 2017 | $51 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Yarrow Bioscience, Inc., its revenue in fiscal 2025 came from these product and service lines: Royalty revenues $570,000 (95%).
Annual report (SEC XBRL) · Dec 2025
Menlo Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2023).
SEC Form D · Nov 2023
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2023
Products and services#
No products or services of Menlo Therapeutics, Inc. are on record.
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| CMEA Ventures VII LP | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Cmea Ventures VII (parallel) LP | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Fmr LLC | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Presidio Partners 2007 GP, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Remeditex Ventures LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| venBio Global Strategic Fund II L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Vivo Capital Fund VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Vivo Capital Surplus Fund VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Vivo Capital VIII, LLC | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 11 investors.
Largest shareholders today
Institutions holding Yarrow Bioscience, Inc. shares, as of Sep 30, 2026.
- Logos Global Management LP$23 M6.74%
- Bellevue Group AG$23 M6.56%
- Perceptive Advisors LLC$18 M5.34%
- Ameriprise Financial Inc$17 M4.85%
- Siren, L.L.C.$15 M4.43%
- Spruce Street Capital LP$14 M3.99%
- venBio Partners LLC$12 M3.64%
- Soleus Capital Management, L.P.$9 M2.74%
- Vanguard Capital Management LLC$8 M2.42%
- Braidwell LP$7 M2.18%
- Driehaus Capital Management LLC$7 M2.00%
- Silverarc Capital Management, LLC$7 M1.98%
- Citadel Advisors LLC$7 M1.95%
- Janus Henderson Group Ltd.$6 M1.86%
- ADAR1 Capital Management, LLC$6 M1.86%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David Domzalski | Executive officer | Nov 2023 |
| Iain Stuart | Executive officer | Nov 2023 |
| Mutya Harsch | Executive officer | Nov 2023 |
| Tyler Zeronda | Executive officer | Nov 2023 |
| Steven L. Basta | Executive officer | Jul 2017 |
| Anthony Bruno | Director | Nov 2023 |
| David Domzalski | Director | Nov 2023 |
| Elisabeth Sandoval | Director | Nov 2023 |
| Patrick Lepore | Director | Nov 2023 |
| Sharon Barbari | Director | Nov 2023 |
| Steven Basta | Director | Nov 2023 |
| Aaron L. Royston | Director | Jul 2017 |
| Albert L. Cha | Director | Jul 2017 |
| David L. Collier | Director | Jul 2017 |
| John L. Creecy | Director | Jul 2017 |
| Ketan L. Patel | Director | Jul 2017 |
| Scott L. Whitcup | Director | Jul 2017 |
| Steven L. Basta | Director | Jul 2017 |
| Ted L. Ebel | Director | Jul 2017 |
Went public since 2018. Its SEC number is that of a company listed on a stock exchange.